Table 1.
Study population baseline characteristics before and after propensity matching.
| Variable | Before propensity score matching | After propensity score matching | ||||
|---|---|---|---|---|---|---|
| DAB | VKA | P value | DAB | VKA | P value | |
| (n = 389) | (n = 510) | (n = 175) | (n = 175) | |||
| Age (years) | 65.1 ± 10.1 | 75.8 ± 6.5 | <0.001 | 60.2 ± 12.0 | 62.2 ± 11.5 | 0.83 |
| Female (%) | 42.8 | 43.1 | 0.68 | 43.07 | 42.09 | 0.71 |
| BMI (kg/m2) | 27.8 ± 7.1 | 27.9 ± 7.1 | 0.82 | 27.8 ± 6.1 | 28.8 ± 6.1 | 0.78 |
| Hypertension (%) | 48.5 | 59.1 | 0.001 | 50.2 | 49.9 | 0.57 |
| CHA2DS2-VASc score | 3.3 ± 1.5 | 4.1 ± 1.4 | 0.02 | 3.5 ± 1.4 | 3.4 ± 1.6 | 0.55 |
| HAS-BLED score | 2.1 ± 1.2 | 3.1 ±1.1 | 0.001 | 2.03 ± 1.2 | 2.05 ±1.4 | 0.55 |
| Diabetes mellitus (%) | 12 | 20 | 0.06 | 12 | 11 | 0.4 |
| Heart failure (%) | 19.8 | 28.2 | 0.001 | 20.9 | 21.2 | 0.8 |
| Prior stroke/TIA (%) | 28.6 | 38.2 | 0.001 | 28.7 | 27.8 | 0.6 |
| Prior MI (%) | 7.1 | 13.1 | 0.02 | 5.5 | 6.3 | 0.6 |
| CrCl (ml/min) | 70.2 ± 19.1 | 61.2 ± 14.5 | 0.001 | 70.2 ± 22.1 | 73.1 ± 20.2 | 0.7 |
| LAD (mm) | 45.3 ± 5.9 | 46.4 ± 5.8 | 0.8 | 46.1 ± 6.3 | 47.2 ± 5.2 | 0.8 |
| LAVI (ml/m2) | 32.1 ± 1.1 | 34.2 ± 0.9 | 0.42 | 32.7 ± 2.2 | 33.5 ± 1.1 | 0.7 |
| LVEF (%) | 55.3 ± 8.5 | 45.2 ± 7.1 | 0.001 | 55.2 ± 5.2 | 53.2 ± 4.2 | 0.8 |
Values are mean ± SD unless otherwise stated.
BMI: body mass index, CrCl: creatinine clearance, DAB: dabigatran etexilate, LAD: left atrial diameter, LAVI:indexed left atrial volume, LVEF: left ventricle ejection fraction, MI: myocardial infarction, SD: standard deviation, TIA: transient ischemic attack, and VKA: vitamin K antagonist.